Suranganie Dharmawardhane

University of Puerto Rico, Medical Sciences Campus

Biochemistry, Genetics and Molecular BiologyMedicine

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 11 papers. Top paper: “Targeting Rac and Cdc42 GEFs in Metastatic Cancer”.

Targeting Rac and Cdc42 GEFs in Metastatic Cancer

Frontiers in Cell and Developmental Biology(2020)10.3389/fcell.2020.00201

N/A

0.721DataRank · unranked

121 citations

Julia I. Medina, Luis Velázquez, Suranganie Dharmawardhane, María del Mar Maldonado

Physiologically-Based Pharmacokinetic/Pharmacodynamic Model of MBQ-167 to Predict Tumor Growth Inhibition in Mice

Pharmaceutics(2020)10.3390/pharmaceutics12100975

N/A

0DataRank · unranked

11 citations

María del Mar Maldonado, Matilde Merino‐Sanjuán, Ailed Cruz‐Collazo, Jean F. Ruiz-Calderón, Víctor Mangas‐Sanjuán +3 more

Simalikalactone D, a Potential Anticancer Compound from Simarouba tulae, an Endemic Plant of Puerto Rico

Plants(2020)10.3390/plants9010093

N/A

0DataRank · unranked

6 citations

Jeyshka Reyes, Isabel Conde, Zulma Ramos, Eunice L. Lozada-Delgado, Ailed M. Cruz +8 more

Rac Inhibition As A Novel Therapeutic Strategy for EGFR/HER2 Targeted Therapy Resistant Breast Cancer

Research Square(2020)10.21203/rs.3.rs-86620/v1

N/A

0DataRank · unranked

0 citations

María del Mar Maldonado, Julia Medina‐Velázquez, Angel Luis Troche‐Torres, Luis Velazquez‐Vega, Nilmary Grafals‐Ruiz +2 more

Efficacy of Rac and Cdc42 Inhibitor MBQ-167 in Triple-negative Breast Cancer

Molecular Cancer Therapeutics(2021)10.1158/1535-7163.mct-21-0348

N/A

0DataRank · unranked

24 citations

Jean F. Ruiz-Calderon, Hector Picon, Luis D. Borrero-Garcia, Irmaris Lopez, Linette Castillo-Pichardo +8 more

Rac inhibition as a novel therapeutic strategy for EGFR/HER2 targeted therapy resistant breast cancer

BMC Cancer(2021)10.1186/s12885-021-08366-7

N/A

0DataRank · unranked

20 citations

María del Mar Maldonado, Julia Medina‐Velázquez, Angel Luis Troche‐Torres, Luis Velázquez, Nilmary Grafals‐Ruiz +2 more

Overcoming Therapy Resistance in HER2‐positive Breast Cancer with the Dual Rac/Cdc42 Inhibitor MBQ‐167

The FASEB Journal(2021)10.1096/fasebj.2021.35.s1.03931

N/A

0DataRank · unranked

0 citations

Michael J. Rivera-Robles, Paula Rocío Vigo‐Morales, Suranganie Dharmawardhane, Luis Velazquez‐Vega

Rac and Cdc42 inhibitors reduce macrophage function in breast cancer preclinical models

Frontiers in Oncology(2023)10.3389/fonc.2023.1152458

N/A

0DataRank · unranked

10 citations

Michael J. Rivera-Robles, Linette Castillo‐Pichardo, Magaly Martínez‐Ferrer, Stephanie Dorta‐Estremera, Suranganie Dharmawardhane +1 more

Data from Efficacy of Rac and Cdc42 Inhibitor MBQ-167 in Triple-negative Breast Cancer

(2023)10.1158/1535-7163.c.6543291

N/A

0DataRank · unranked

0 citations

Jean F. Ruiz-Calderón, Hector Picon, Luis D. Borrero-García, Irmaris Lopez, Linette Castillo‐Pichardo +8 more

Data from Efficacy of Rac and Cdc42 Inhibitor MBQ-167 in Triple-negative Breast Cancer

(2023)10.1158/1535-7163.c.6543291.v1

N/A

0DataRank · unranked

0 citations

Jean F. Ruiz-Calderón, Hector Picon, Luis D. Borrero-García, Irmaris Lopez, Linette Castillo‐Pichardo +8 more

Efficacy and delivery strategies of the dual Rac/Cdc42 inhibitor MBQ-167 in HER2 overexpressing breast cancer

Translational Oncology(2024)10.1016/j.tranon.2024.101928

N/A

0DataRank · unranked

5 citations

Michael J. Rivera-Robles, Annelis O. Sánchez-Álvarez, Pablo E. Vivas‐Mejía, Miciely Aponte-Reyes, Ailed Cruz‐Collazo +6 more